Dolasetron mesylate
![]() |
- ₹9428.58 - ₹38017.4
- Product name: Dolasetron mesylate
- CAS: 115956-13-3
- MF: C20H26N2O7S
- MW: 438.49
- EINECS:601-404-5
- MDL Number:MFCD01718979
- Synonyms:DOLASETRON MESYLATE:DOLASETRON;Dolasetron mesylate/(2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate monomethanesulfonate;(2alpha,6alpha,8alpha,9abeta)-Octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl-1H-indole-3-carboxylate monomethanesulfonate;Dolasetron Mesylate (200 mg);Dolasetron Mesylate hydrate;Dalasetron (Mesylate);Anzemet hydrate;Dolasetron methanesulfonate hydrate
2 prices
Selected condition:
Brand
- Sigma-Aldrich(India)
Package
- 10MG
- 50MG
- ManufacturerSigma-Aldrich(India)
- Product numberD9571
- Product descriptionDolasetron mesylate hydrate ≥98% (HPLC), powder
- Packaging10MG
- Price₹9428.58
- Updated2022-06-14
- Buy
- ManufacturerSigma-Aldrich(India)
- Product numberD9571
- Product descriptionDolasetron mesylate hydrate ≥98% (HPLC), powder
- Packaging50MG
- Price₹38017.4
- Updated2022-06-14
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Sigma-Aldrich(India) | D9571 | Dolasetron mesylate hydrate ≥98% (HPLC), powder | 10MG | ₹9428.58 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | D9571 | Dolasetron mesylate hydrate ≥98% (HPLC), powder | 50MG | ₹38017.4 | 2022-06-14 | Buy |
Properties
Melting point :278°
storage temp. :Sealed in dry,2-8°C
solubility :H2O: >30mg/mL
form :powder
color :white to off-white
CAS DataBase Reference :115956-13-3(CAS DataBase Reference)
storage temp. :Sealed in dry,2-8°C
solubility :H2O: >30mg/mL
form :powder
color :white to off-white
CAS DataBase Reference :115956-13-3(CAS DataBase Reference)
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|
Description
Dolasetron was launched as Anzemet in Australia and the US for the prevention of nausea and vomiting in chemotherapy patients. It is a highly potent and very selective antagonist of 5-HT3 receptors ; it is the sixth in this class of compounds to be marketed for the treatment of chemotherapy-induced emesis. The last two approved in this class were Nazasetron (1994) and Ramosetron (1996). Anzemet was prepared by a seven step sequence from a cyclopentenecarboxylic ester via a Robinson-Schopf cyclisation of a dialdehyde into a key 9-azabicyclo[3.3.l]nonan-3-one. In a clinical study with 164 cancer patients treated with Dolasetron mesylate prior to Cisplatin, single doses of 10- 50 mg achieved major control of nausea and emesis in 73% of subjects and were well tolerated. Results from pharmacokinetic studies in humans showed that the clinical effects and duration of action seem to be due mainly to a major plasma metabolite rapidly formed and very potent itself, the (+) enantiomeric alcohol obtained by enzymatic reduction of the cyclic ketone.Related product price
- Trifluoromethanesulfonic acid
₹2015.05-108359.05 - Imatinib
₹5100-26800 - Pazufloxacin mesilate
₹5300-9200